Skip to NavigationSkip to content

Boehringer's France restructure will cull over 300 jobs

Published on 11/12/18 at 10:35am

Boehringer Ingelheim is set to follow in the recent steps of Sanofi with the announcement of a cull of over 300 employees in France – around 10% of the company’s total workforce in the country.

The German drug company confirmed the plans to unions, explaining that the move is designed to reorganise operations in and around its hub in the French city of Lyon.

The restructure comes in the wake of an asset swap between Boehringer and Sanofi, with the former trading its consumer health division for the latter’s animal health arm Merial last year – a transaction worth $20 billion.

In total, Sanofi intends to axe 327 positions from a total of 2,800, which will also make room for the introduction of 32 new roles. The plan was confirmed by Jean Scheftsik de Szolnok, Boehringer’s Chairman for France, who also noted that those affected would be offered voluntary severance packages, though he could not say exactly when this would be the case.

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches